Generex, makers of Oral-lyn™ oral insulin spray, have published the results of their study on the effectiveness of Oral-lyn™ in Type-1 diabetics.
The title of the published abstract is “Comparison of Oral Insulin Spray and Subcutaneous Regular Insulin at Mealtime in Type 1 Diabetes,” authored by Jaime Guevara-Aguirre, M.D., Marco Guevara-Aguirre, M.D., Jeannette Saavedra, M.D., Gerald Bernstein M.D., and Arlan L. Rosenbloom, M.D.
The published conclusion is that regular insulin and Generex Oral-lyn had similar glucodynamic effects in subjects with Type-1 Diabetes Mellitus receiving twice-daily insulin analogue as baseline therapy. Intensive monitoring and timely corrections with additional snacks, additional sc regular insulin, or Generex Oral-lyn(tm) puffs resulted in appropriate glycemic control as assessed by individual daily glycemic responses and especially, normal preprandial glycation decreased, but not significantly.
“This publication is significant in that it shows consistently and clearly that equivalent amounts of Generex Oral-lyn and injected regular insulin will yield comparable blood glucose control,” said Dr. Gerald Bernstein, Generex’s Vice President of Medical Affairs and a co-author of the article.